GLAXO
Invest with MTF
Invest Now
Invest in GlaxoSmithKline Pharmaceuticals with 3.24X leverage
Performance
- Low
- ₹2,610
- High
- ₹2,720
- 52 Week Low
- ₹1,968
- 52 Week High
- ₹3,516
- Open Price₹2,622
- Previous Close₹2,623
- Volume114,978
- 50 DMA₹2,475.76
- 100 DMA₹2,554.65
- 200 DMA₹2,627.51
Investment Returns
- Over 1 Month + 13.79%
- Over 3 Month + 6.28%
- Over 6 Month + 1.82%
- Over 1 Year + 26.05%
Smart Investing Starts Here Start SIP with GlaxoSmithKline Pharmaceuticals for Steady Growth!
GlaxoSmithKline Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 44.8
- PEG Ratio
- 2.4
- Market Cap Cr
- 45,728
- P/B Ratio
- 26.8
- Average True Range
- 83.06
- EPS
- 59.37
- Dividend Yield
- 1.6
- MACD Signal
- 1.28
- RSI
- 71.46
- MFI
- 69.04
GlaxoSmithKline Pharmaceuticals Financials
GlaxoSmithKline Pharmaceuticals Technicals
EMA & SMA
Current Price
₹2,699.30
+
76.4
(2.91%)
- Bearish Moving Average 1
- Bullish Moving Average 15
- 20 Day
- ₹2,464.76
- 50 Day
- ₹2,475.76
- 100 Day
- ₹2,554.65
- 200 Day
- ₹2,627.51
Resistance and Support
2676.37
- R3 2,852.53
- R2 2,786.17
- R1 2,742.73
- S1 2,632.93
- S2 2,566.57
- S3 2,523.13
GlaxoSmithKline Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
GlaxoSmithKline Pharmaceuticals F&O
About GlaxoSmithKline Pharmaceuticals
- NSE Symbol
- GLAXO
- BSE Symbol
- 500660
- Managing Director
- Mr. B Akshikar
- ISIN
- INE159A01016
Similar Stocks to GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals FAQs
GlaxoSmithKline Pharmaceuticals share price is ₹2,699 As on 12 February, 2026 | 01:29
The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹45727.8 Cr As on 12 February, 2026 | 01:29
The P/E ratio of GlaxoSmithKline Pharmaceuticals is 44.8 As on 12 February, 2026 | 01:29
The PB ratio of GlaxoSmithKline Pharmaceuticals is 26.8 As on 12 February, 2026 | 01:29
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.